ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )

1
ISPOR POLAND CHAPTERPolish Society of
Pharmacoeconomics (PTFe )
2
Accepted multidisciplinary methodology
International examples
Pharmacoeconomics in Poland
Optimizing pharmacotherapy through rational drugs
management
3
Pharmacoeconomics in Poland
Polish terminology
Educational opportunities
Regulations
Methodology/ Standardization
Existing resources
4
REGULATIONS

• Act on Health Services Financed from Public
  Sources
• Necessity of justyfying proposed price
• Evidence on clinical efficiacy, cost-
  effectiveness and budget impact analysis (for
  innovative drugs)
• Act on Prices
• Regulations concerning Health Technology
  Assessment Agency
• Economic evaluation including cost analysis
• Influence on financing from public sources
• Requirements concerning Treatment Programmes
  financed by the National Health Fund
• Defining cost-endpoint relationship

5
METHODOLOGY/TERMINOLOGY

1. Polish Guidlines for conducting pharmacoeconomic
   evaluations (2000) approved by ISPOR Polish
   Chapter
2. The Polish Dictionary of Pharmacoeconomics 1st
   and 2nd editions
3. Textbooks and manuals

6
REIMBURSEMENT SYSTEM
Limit prices for reimbursed drugs
The same active substance, different market
price.
Generic limit price
Different active substances, the same effect,
different market price.
Therapeutic limit price
Basic and supplementary list
Fixed charge
7
ISPOR POLAND CHAPTER in 2005-2006

• Organizing the 3rd Scientific Conference of the
  Polish Society of Pharmacoeconomics
  (Reimbursement systems in EU countries
  discussion about activities of the Society
  members in working groups of ISPOR
• Working on the 4th Scientific Conference of the
  Polish Society of Pharmacoeconomics (focused on
  pharmacoeconomics and economic evaluation of
  heath care programs prof. Paul Kind as a main
  speaker Patient reported outcomes and quality
  of life inviting Czech and Russian ISPOR
  Chapters Presidents
• Creating Student Section within the Polish
  Society of Pharmacoeconomics with 25 members in
  order to promote interest and awareness about
  pharmacoeconomics, health outcome research to
  various disciplines across members of
  health-related organizations and universities in
  Poland
• Educational support of Student Section by PTFE
  lectures
• Pharmacoeconomics in Polish perspective
• Health and economics prof. Tomasz Hermanowski

8
ISPOR POLAND CHAPTER in 2005-2006

• Cooperation with medical societies in educational
  area lectures on pharmacoeconomics for relevant
  scientific and medical societies
• Discussion with representatives of the Ministry
  of Health about principles of pricing and
  reimbursement system in Poland in relation to
  pharmacoeconomics
• Discussion with the Association of Pharmaceutical
  Industry in Poland on the Code of Marketing
  Ethics.
• Stating an objection against the use of
  pharmacoeconomic studies as a marketing tool.
• Representing the Polish Society of
  Pharmacoeconomics on the following conferences
• the 7th Congress of European Association for
  Clinical Pharmacology and Thearpautics
• Lectures about the role of pharmacoeconomics in
  drug policy,
• Conference of Quality  Management Center, Cracow,
• Workshop for hospitals directors and
  pharmacists Pharmacoeconomics in atreatment
  process, Oct. 2006
• participation in experts panel How clinical
  trials for new drugs should be financing?, Oct.
  2006